Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation.
An alternative clinical management strategy and cost analysis model is presented for patients with atrial fibrillation of >2 days' duration who may benefit from immediate cardioversion with self-administered low-molecular-weight heparin (enoxaparin) as a bridge antithrombotic therapy to warfarin, after a negative transesophageal echo-cardiography (TEE) screening for thrombus. Assuming no difference in stroke or bleeding rates, our cost minimization model shows that the TEE-guided enoxaparin treatment costs are $1353 lower per patient than an intravenous unfractionated heparin approach. Sensitivity analyses for stroke and bleeding reveal that the treatment-cost economic dominance of the TEE-guided enoxaparin approach may be enhanced by an expected improvement in clinical outcome.
Department of Cardiology, Cardiovascular Imaging Center; the Department of Vascular Medicine, Clinical Thrombosis Section; and Biostatistics and Epidemiology; The Cleveland Clinic Foundation.
R D
RD
Murray
S R
SR
Deitcher
A
A
Shah
S E
SE
Jasper
M
M
Bashir
R A
RA
Grimm
A L
AL
Klein
D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000000981:diagnostic imaging* / Q000628:therapy*; D003362:Cost-Benefit Analysis; D017548:Echocardiography, Transesophageal / Q000191:economics*; D004554:Electric Countershock / Q000191:economics*; D017984:Enoxaparin / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D015912:Thrombolytic Therapy / Q000191:economics*; D016896:Treatment Outcome
D000925:Anticoagulants; D017984:Enoxaparin